IDH1 and astrocytoma (excluding glioblastoma): In multivariate analysis, after adjusting for IDH1 mutation, tumour grade, gender and age, YAP1 levels were an independent prognostic factor for chemotherapy-treated recurrent astrocytoma (HR (95% CI): 4.06 (1.32–12.27), p = 0.013).